| Item |
Information |
|
Drug Groups
|
approved; investigational |
|
Description
|
(6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione. A synthetic progestational hormone used in veterinary practice as an estrus regulator. [PubChem] |
| Indication |
Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens. |
| Pharmacology |
Medroxyprogesterone is a synthetic progestin more potent than progesterone. |
| Toxicity |
Side effects include loss of bone mineral density, BMD changes in adult women, bleeding irregularities, cancer risks, and thromboembolic disorders. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic |
| Absorption |
Rapidly absorbed from GI tract |
| Half Life |
50 days |
| Protein Binding |
90% |
| Elimination |
Following oral dosing, MPA is extensively metabolized in the liver via hydroxylation, with subsequent conjugation and elimination in the urine. Most MPA metabolites are excreted in the urine as glucuronide conjugates with only minor amounts excreted as sulfates. |
| Clearance |
* 64110 +/- 42662 mL/min [postmenopausal women under fasting conditions with a single Dose of 2 × 10 mg]
* 74123 +/- 35126 mL/min [postmenopausal women under fasting conditions with a single Dose of 8 × 2.5 mg]
* 41963 +/- 38402 mL/min [postmenopausal women following daily administration of one PROVERA 10 mg tablet for 7 days] |
| External Links |
|